enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report)’s stock price dropped 14.4% during mid-day trading on Monday . The stock traded as low as $0.3390 and last traded at $0.2750. Approximately 300 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 17,162 shares. The stock had previously closed at $0.3213.
enGene Price Performance
The stock has a 50-day moving average of $0.26 and a 200 day moving average of $1.82.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
See Also
- Five stocks we like better than enGene
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
